

Wolfgang Sadee

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8088290/wolfgang-sadee-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122
papers

6,866
citations

43
h-index

81
g-index

129
ext. papers

7,529
ext. citations

5.1
avg. IF

5.6
L-index

#	Paper	IF	Citations
122	Interpreting coronary artery disease GWAS results: A functional genomics approach assessing biological significance.. <i>PLoS ONE</i> , 2022 , 17, e0244904	3.7	0
121	Drug Abuse in Pakistan 2022 , 1-22		
120	Functional CYP3A variants affecting tacrolimus trough blood concentrations in Chinese renal transplant recipients. <i>Pharmacogenomics Journal</i> , 2021 , 21, 376-389	3.5	2
119	Association of Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Anticancer Research</i> , 2020 , 40, 5707-5713	2.3	1
118	Challenges of Immune Response Diversity in the Human Population Concerning New Tuberculosis Diagnostics, Therapies, and Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 139	5.9	0
117	Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management. <i>Molecules</i> , 2020 , 25,	4.8	4
116	Pharmacological Prevention of Neonatal Opioid Withdrawal in a Pregnant Guinea Pig Model. <i>Frontiers in Pharmacology</i> , 2020 , 11, 613328	5.6	1
115	Significant association of DRD2 enhancer variant rs12364283 with heroin addiction in a Pakistani population. <i>Annals of Human Genetics</i> , 2019 , 83, 367-372	2.2	3
114	Nicotine Dependence and the CHRNA5/CHRNA3/CHRN4 Nicotinic Receptor Regulome 2019 , 347-353		
113	Ligand-Free Estrogen Receptor (ESR1) as Master Regulator for the Expression of CYP3A4 and Other Cytochrome P450 Enzymes in the Human Liver. <i>Molecular Pharmacology</i> , 2019 , 96, 430-440	4.3	16
112	Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2019 , 12, 280-289	3.3	3
111	Association of Regulatory Genetic Variants for Protein Kinase C δ with Mortality and Drug Efficacy in Patients with Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2019 , 33, 693-700	3.9	
110	CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels. <i>Pharmacogenetics and Genomics</i> , 2019 , 29, 39-47	1.9	13
109	Testing genetic modifiers of behavior and response to atomoxetine in autism spectrum disorder with ADHD. <i>Journal of Developmental and Physical Disabilities</i> , 2018 , 30, 355-371	1.5	6
108	Whole Transcriptome Profiling: An RNA-Seq Primer and Implications for Pharmacogenomics Research. <i>Clinical and Translational Science</i> , 2018 , 11, 153-161	4.9	5
107	Alpha-synuclein mRNA isoform formation and translation affected by polymorphism in the human SNCA 3RUTR. <i>Molecular Genetics & Genomic Medicine</i> , 2018 , 6, 565	2.3	6
106	AmpliSeq transcriptome analysis of human alveolar and monocyte-derived macrophages over time in response to Mycobacterium tuberculosis infection. <i>PLoS ONE</i> , 2018 , 13, e0198221	3.7	15

105	Combined genetic influence of the nicotinic receptor gene cluster CHRNA5/A3/B4 on nicotine dependence. <i>BMC Genomics</i> , 2018 , 19, 826	4.5	8
104	Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7 β -Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression. <i>Circulation Genomic and Precision Medicine</i> , 2018 , 11, e002082	5.2	6
103	Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. <i>BMC Medical Genomics</i> , 2018 , 11, 55	3.7	4
102	Regulatory Variants Modulate Protein Kinase C α (PRKCA) Gene Expression in Human Heart. <i>Pharmaceutical Research</i> , 2017 , 34, 1648-1657	4.5	7
101	Expression and splicing of ABC and SLC transporters in the human blood-brain barrier measured with RNAseq. <i>European Journal of Pharmaceutical Sciences</i> , 2017 , 103, 47-51	5.1	21
100	CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure. <i>Pharmaceutical Research</i> , 2017 , 34, 1615-1625	4.5	21
99	Alveolar macrophages from tuberculosis patients display an altered inflammatory gene expression profile. <i>Tuberculosis</i> , 2017 , 107, 156-167	2.6	21
98	Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. <i>Scientific Reports</i> , 2017 , 7, 16068	4.9	4
97	The CHRNA5/CHRNA3/CHRNA4 Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations. <i>Human Mutation</i> , 2017 , 38, 112-119	4.7	19
96	Elemental Ingredients in the Macrophage Cocktail: Role of ZIP8 in Host Response to Mycobacterium tuberculosis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	14
95	Intronic SNP in ESR1 encoding human estrogen receptor alpha is associated with brain ESR1 mRNA isoform expression and behavioral traits. <i>PLoS ONE</i> , 2017 , 12, e0179020	3.7	10
94	Non-linear interactions between candidate genes of myocardial infarction revealed in mRNA expression profiles. <i>BMC Genomics</i> , 2016 , 17, 738	4.5	11
93	Preferential Delivery of an Opioid Antagonist to the Fetal Brain in Pregnant Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016 , 358, 22-30	4.7	6
92	Human Bacterial Artificial Chromosome (BAC) Transgenesis Fully Rescues Noradrenergic Function in Dopamine β -Hydroxylase Knockout Mice. <i>PLoS ONE</i> , 2016 , 11, e0154864	3.7	7
91	Gene expression profiling of brain samples from patients with Lewy body dementia. <i>Biochemical and Biophysical Research Communications</i> , 2016 , 479, 875-880	3.4	14
90	Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in <i>Psychopharmacology</i> 232, 305-314, 2014. <i>Psychopharmacology</i> , 2015 , 232, 1493-4	4.7	
89	Analyzing allele specific RNA expression using mixture models. <i>BMC Genomics</i> , 2015 , 16, 566	4.5	5
88	The epigenome, 4D nucleome and next-generation neuropsychiatric pharmacogenomics. <i>Pharmacogenomics</i> , 2015 , 16, 1649-69	2.6	14

87	RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. <i>BMC Genomics</i> , 2015 , 16, 990	4.5	19
86	Conditional entropy in variation-adjusted windows detects selection signatures associated with expression quantitative trait loci (eQTLs). <i>BMC Genomics</i> , 2015 , 16 Suppl 8, S8	4.5	0
85	Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms. <i>PLoS ONE</i> , 2015 , 10, e0136798	3.7	9
84	Cladograms with Path to Event (ClAPTE): a novel algorithm to detect associations between genotypes or phenotypes using phylogenies. <i>Computers in Biology and Medicine</i> , 2015 , 58, 1-13	7	1
83	Missing heritability of common diseases and treatments outside the protein-coding exome. <i>Human Genetics</i> , 2014 , 133, 1199-215	6.3	47
82	Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder. <i>Research in Developmental Disabilities</i> , 2014 , 35, 1658-65	2.7	28
81	Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. <i>Human Molecular Genetics</i> , 2014 , 23, 268-78	5.6	78
80	DRD2/CHRNA5 interaction on prefrontal biology and physiology during working memory. <i>PLoS ONE</i> , 2014 , 9, e95997	3.7	14
79	Design and implementation of a randomized controlled trial of genomic counseling for patients with chronic disease. <i>Journal of Personalized Medicine</i> , 2014 , 4, 1-19	3.6	17
78	Genomic architecture of pharmacological efficacy and adverse events. <i>Pharmacogenomics</i> , 2014 , 15, 2025-48	2.6	18
77	Regulatory polymorphisms in human DBH affect peripheral gene expression and sympathetic activity. <i>Circulation Research</i> , 2014 , 115, 1017-25	15.7	17
76	Whole transcriptome RNA-Seq allelic expression in human brain. <i>BMC Genomics</i> , 2013 , 14, 571	4.5	43
75	Bridging material and biological sciences: the legacy of Hans Peter Merkle. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013 , 85, 3-4	5.7	1
74	Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex. <i>Biological Psychiatry</i> , 2013 , 73, 546-54	7.9	50
73	The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. <i>Clinical Pharmacology and Therapeutics</i> , 2013 , 94, 207-10	6.1	128
72	Gene-gene-environment interactions between drugs, transporters, receptors, and metabolizing enzymes: Statins, SLCO1B1, and CYP3A4 as an example. <i>Journal of Pharmaceutical Sciences</i> , 2013 , 102, 2924-9	3.9	8
71	Expression of mRNA transcripts encoding membrane transporters detected with whole transcriptome sequencing of human brain and liver. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 269-78	1.9	5
70	CYP2D6 expression is regulated by polymorphisms that affect splicing and transcription: new biomarkers for CYP2D6 activity. <i>FASEB Journal</i> , 2013 , 27, 663.6	0.9	

69	Innate immune gene polymorphisms in tuberculosis. <i>Infection and Immunity</i> , 2012 , 80, 3343-59	3.7	221
68	Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. <i>PLoS ONE</i> , 2012 , 7, e31930	3.7	45
67	The Making of a CYP3A Biomarker Panel for Guiding Drug Therapy. <i>Journal of Personalized Medicine</i> , 2012 , 2, 175-91	3.6	19
66	Human N-acetyltransferase 1 *10 and *11 alleles increase protein expression through distinct mechanisms and associate with sulfamethoxazole-induced hypersensitivity. <i>Pharmacogenetics and Genomics</i> , 2011 , 21, 652-64	1.9	39
65	β-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. <i>Pain Medicine</i> , 2011 , 12, 1727-37	2.8	20
64	Dopamine transporter gene variant affecting expression in human brain is associated with bipolar disorder. <i>Neuropsychopharmacology</i> , 2011 , 36, 1644-55	8.7	105
63	Nicotinic β receptor subunit mRNA expression is associated with distant 5'upstream polymorphisms. <i>European Journal of Human Genetics</i> , 2011 , 19, 76-83	5.3	54
62	Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse. <i>Neuropsychopharmacology</i> , 2011 , 36, 753-62	8.7	111
61	Pharmacogenomic biomarkers: validation needed for both the molecular genetic mechanism and clinical effect. <i>Pharmacogenomics</i> , 2011 , 12, 675-80	2.6	9
60	Genetically determined interaction between the dopamine transporter and the D2 receptor on prefronto-striatal activity and volume in humans. <i>Journal of Neuroscience</i> , 2009 , 29, 1224-34	6.6	78
59	β-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice. <i>Life Sciences</i> , 2009 , 85, 413-20	6.8	10
58	Measuring cis-acting regulatory variants genome-wide: new insights into expression genetics and disease susceptibility. <i>Genome Medicine</i> , 2009 , 1, 116	14.4	13
57	Allelic mRNA expression of sortilin-1 (SORL1) mRNA in Alzheimer's autopsy brain tissues. <i>Neuroscience Letters</i> , 2008 , 448, 120-4	3.3	
56	MicroRNAs modulate the chemosensitivity of tumor cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1-9	6.1	318
55	The human zinc transporter SLC39A8 (Zip8) is critical in zinc-mediated cytoprotection in lung epithelia. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2008 , 294, L1127-36	5.8	104
54	Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. <i>Blood</i> , 2008 , 112, 1013-21	2.2	163
53	The re-emerging concept of personalized healthcare. <i>Personalized Medicine</i> , 2008 , 5, 457-469	2.2	4
52	Drug therapy and personalized health care: pharmacogenomics in perspective. <i>Pharmaceutical Research</i> , 2008 , 25, 2713-9	4.5	14

51	Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 781-91	1.9	78
50	Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. <i>Molecular Pharmacology</i> , 2007 , 72, 1637-46	4.3	24
49	Chemogenomics of Sensitivity and Resistance to Anticancer Drugs. <i>Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics</i> , 2007 , 5, 11-19		
48	Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007 , 104, 20552-7	11.5	337
47	MicroRNA expression profiles for the NCI-60 cancer cell panel. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1483-91	6.1	215
46	Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007 , 321, 544-52	4.7	69
45	Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 1896-906	8.3	36
44	Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain: dissection of epigenetic and genetic factors. <i>Human Molecular Genetics</i> , 2006 , 15, 2636-49	5.6	89
43	Network analysis using transitive closure: New methods for exploring networks. <i>Journal of Statistical Computation and Simulation</i> , 2006 , 76, 539-551	0.9	2
42	5-Aza-2Pdeoxycytidine and depsipeptide synergistically induce expression of BIK (BCL2-interacting killer). <i>Biochemical and Biophysical Research Communications</i> , 2006 , 351, 455-61	3.4	13
41	Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 735-45	1.9	79
40	Protein therapeutics: new applications for pharmacogenetics. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 507-21	64.1	59
39	Searching for polymorphisms that affect gene expression and mRNA processing: example ABCB1 (MDR1). <i>AAPS Journal</i> , 2006 , 8, E515-20	3.7	82
38	Prediction of anticancer drug potency from expression of genes involved in growth factor signaling. <i>Pharmaceutical Research</i> , 2006 , 23, 336-49	4.5	24
37	How specific are "target-specific" drugs? Celecoxib as a case in point. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2006 , 6, 196-8		
36	Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. <i>Cancer Research</i> , 2005 , 65, 7446-54	10.1	224
35	Pharmacogenetics/genomics and personalized medicine. <i>Human Molecular Genetics</i> , 2005 , 14 Spec No. 2, R207-14	5.6	140
34	Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. <i>Life Sciences</i> , 2005 , 76, 1427-37	6.8	83

33	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 693-704	1.9	355
32	Polymorphisms affecting gene regulation and mRNA processing: broad implications for pharmacogenetics 2005 , 106, 19-38		74
31	In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005 , 313, 1150-62	4.7	73
30	Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. <i>Journal of Biological Chemistry</i> , 2005 , 280, 32618-24	5.4	444
29	Opioid receptor homo- and heterodimerization in living cells by quantitative bioluminescence resonance energy transfer. <i>Molecular Pharmacology</i> , 2005 , 67, 2173-84	4.3	131
28	Pharmacogenomics: harbinger for the era of personalized medicine?. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2005 , 5, 140-3		6
27	Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. <i>Pharmacogenetics and Genomics</i> , 2005 , 15, 693-704	1.9	162
26	Genetic variants of the human H+/dipeptide transporter PEPT2: analysis of haplotype functions. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 311, 1088-96	4.7	76
25	Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. <i>Cancer Research</i> , 2004 , 64, 4294-301	10.1	244
24	Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004 , 308, 512-20	4.7	74
23	Transporter and ion channel gene expression after Caco-2 cell differentiation using 2 different microarray technologies. <i>AAPS Journal</i> , 2004 , 6, e21	3.7	25
22	Growth factor signaling and resistance to cancer chemotherapy. <i>Current Topics in Medicinal Chemistry</i> , 2004 , 4, 1347-56	3	43
21	Single nucleotide polymorphism genotyping using allele-specific PCR and fluorescence melting curves. <i>BioTechniques</i> , 2003 , 34, 1068-72	2.5	96
20	Messenger RNA expression of transporter and ion channel genes in undifferentiated and differentiated Caco-2 cells compared to human intestines. <i>Pharmaceutical Research</i> , 2003 , 20, 3-15	4.5	42
19	Differential effects of mu-opioid receptor ligands on Ca(2+) signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002 , 302, 1002-12	4.7	30
18	Inverse agonists and neutral antagonists at mu opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. <i>Journal of Neurochemistry</i> , 2001 , 77, 1590-600	6	111
17	Evolutionary relationships among G protein-coupled receptors using a clustered database approach. <i>AAPS PharmSci</i> , 2001 , 3, E12		43
16	Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 2270-9	27.4	467

15	Nuclear Ca ²⁺ /calmodulin translocation activated by mu-opioid (OP3) receptor. <i>Journal of Neurochemistry</i> , 2000 , 74, 1418-25	6	38
14	G-protein coupling of Epioid receptors (OP3): elevated basal signalling activity. <i>Biochemical Journal</i> , 2000 , 348, 531	3.8	26
13	G-protein coupling of Epioid receptors (OP3): elevated basal signalling activity. <i>Biochemical Journal</i> , 2000 , 348, 531-537	3.8	67
12	Molecular modeling of G-protein coupled receptor kinase 2: docking and biochemical evaluation of inhibitors. <i>AAPS PharmSci</i> , 2000 , 2, E2		13
11	Pharmacogenomics: the promise of personalized medicine. <i>AAPS PharmSci</i> , 2000 , 2, E4		133
10	Human proton/oligopeptide transporter (POT) genes: identification of putative human genes using bioinformatics. <i>AAPS PharmSci</i> , 2000 , 2, E16		38
9	Sequestration of dopamine D2 receptors depends on coexpression of G-protein-coupled receptor kinases 2 or 5. <i>FEBS Journal</i> , 1999 , 260, 112-9		91
8	Genomics and drugs: finding the optimal drug for the right patient. <i>Pharmaceutical Research</i> , 1998 , 15, 959-63	4.5	15
7	Sequence alignments of the H(+)-dependent oligopeptide transporter family PTR: inferences on structure and function of the intestinal PET1 transporter. <i>Pharmaceutical Research</i> , 1997 , 14, 388-400	4.5	22
6	Evolutionary relationships among proteins probed by an iterative neighborhood cluster analysis (INCA). Alignment of bacteriorhodopsins with the yeast sequence YRO2. <i>Pharmaceutical Research</i> , 1997 , 14, 1533-41	4.5	17
5	Residues specifically involved in down-regulation but not internalization of the m1 muscarinic acetylcholine receptor. <i>Journal of Neurochemistry</i> , 1997 , 68, 601-9	6	25
4	Basal phosphorylation of mu opioid receptor is agonist modulated and Ca ²⁺ -dependent. <i>FEBS Letters</i> , 1996 , 387, 53-7	3.8	35
3	Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. <i>Life Sciences</i> , 1994 , 54, PL339-50	6.8	106
2	Opiate antagonist receptor binding in vivo: evidence for a new receptor binding model. <i>Brain Research</i> , 1980 , 199, 49-61	3.7	95
1	Pharmacological prevention of neonatal opioid withdrawal in a pregnant guinea pig model		2